Levetiracetam Neuropharma (Levetiracetam)

Levetiracetam is an antiepileptic medication that modulates neuronal excitability to control seizure activity across several epilepsy syndromes.

• Partial‑onset seizures: reduces frequency and severity of focal seizures, improving daily functioning.
• Generalized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy, supporting seizure control.
• Myoclonic seizures: decreases rapid, involuntary muscle jerks associated with myoclonic epilepsy, enhancing safety.
• Adjunct therapy in epilepsy: can be combined with other antiepileptics when monotherapy does not achieve adequate control.

• Levetiracetam binds selectively to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent exocytosis, stabilizing synaptic transmission and reducing excessive neuronal firing. By limiting the release of excitatory neurotransmitters, the drug diminishes hyper‑excitability in the central nervous system, thereby preventing the initiation and propagation of seizure activity. The precise downstream effects remain under investigation, but the overall result is a net anticonvulsant effect without significant interaction with ion channels or G‑protein coupled receptors.

Levetiracetam may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: persistent tiredness or lack of energy.
• Headache: mild to moderate cranial pain.
• Irritability: mood changes including agitation or anger.
• Nausea: upset stomach with possible vomiting.
• Somnolence: increased sleepiness or drowsiness.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Mood or behavior changes: depression, suicidal thoughts, or aggression.
• Blood disorders: thrombocytopenia, neutropenia, or anemia.
• Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
• Hepatic or renal dysfunction: abnormal liver enzymes or reduced kidney function.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess clearance and adjust dose in patients with impaired renal function.
• Pregnancy: Category B; use only when benefits outweigh potential fetal risk.
• Psychiatric history: monitor for mood changes or suicidal thoughts in patients with prior psychiatric disorders.
• Concomitant CNS depressants: watch for added sedation when combined with other CNS‑depressant agents.
• Discontinuation: taper gradually under medical supervision to avoid seizure worsening.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Levetiracetam may interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Co‑administration with other antiepileptic drugs that significantly lower seizure threshold may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

• Carbamazepine, phenytoin, phenobarbital: enzyme inducers that can decrease levetiracetam plasma concentrations.
• Valproic acid: may increase levetiracetam levels modestly.
• CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation.
• Alcohol: can potentiate central nervous system effects.
• Renal‑clearing drugs (e.g., aminoglycosides): may affect renal function and levetiracetam elimination.